Systemic chronic low-grade inflammation and the development of thyroid autoantibodies: Immunological mechanisms and biomarker perspectives
Abstract
Thyroid autoantibodies, chiefly antibodies against thyroid peroxidase (TPOAb), thyroglobulin (TgAb), and the thyroid-stimulating hormone receptor (TRAb), are central serological hallmarks of autoimmune thyroid disease (AITD). Their presence may precede overt hypothyroidism or hyperthyroidism by years, yet the systemic conditions that facilitate their emergence remain incompletely understood. Systemic chronic lowgrade inflammation (SCLGI), a persistent and subclinical inflammatory state characterized by modest elevations in circulating cytokines, acute-phase reactants, and innate immune activation, has emerged as a plausible upstream contributor. Obesity, insulin resistance, aging, dysbiosis, chronic psychosocial stress, and cardiometabolic disease all promote SCLGI and may lower the threshold for thyroid-directed loss of tolerance. This review synthesizes current evidence linking SCLGI to thyroid autoantibody development, emphasizing cytokine-driven antigen presentation, Th1/Th17–Treg disequilibrium, B-cell activation, oxidative stress, and altered mucosal immune signaling. We further evaluate the potential of conventional inflammatory indicators, cytokine panels, hematologic ratios, adipokines, and composite multiomics signatures as biomarkers for risk stratification. Existing evidence is biologically coherent but remains largely cross-sectional; therefore, longitudinal studies that distinguish autoantibody initiation from progression to clinical disease are urgently required. A biomarker-guided framework integrating inflammatory burden with genetic, metabolic, and thyroid-specific factors may improve early identification and prevention of AITD.